Immune Checkpoint Inhibitors Market Size to Hit USD 140.89 Bn by 2030

According to Latest Study, the global immune checkpoint inhibitors market was surpassed at USD 29.89 billion in 2021 and is expected to hit around USD 140.89 billion by 2030, growing at a CAGR of 16.80% from 2022 to 2030.

Key Findings of the study

• Based on type, the PD-L1 inhibitor segment is expected to experience rapid growth in the market, and is projected to grow at a CAGR of 16.9% from 2021 to 2030.
• Based on application, the lung cancer segment held approximately 17.5% share of the global immune checkpoint inhibitors market in 2020, and is expected to remain dominant throughout the forecast period.
• Based on region, Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 18.4% during the forecast period.

Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/39336

Checkpoint inhibitor is a type of drug used in immunotherapy, which helps block the proteins present on tumor cells as they affect functioning of the immune system. Immune checkpoint inhibitor drugs block different checkpoint proteins including CTLA-4 (cytotoxic T lymphocyte associated protein 4), PD-1 (programmed cell death protein 1), and PD-L1 (programmed death ligand 1). Immune checkpoint inhibitor targets checkpoint proteins and assists the immune system to recognize and attack cancer cells. 

Immune checkpoint inhibitors are expected to exhibit significant market growth during the forecast period, owing to growth in demand for ideal therapeutics for treatment of cancer, favorable reimbursement policies provided by manufacturers & insurance providers in some countries, and surge in prevalence of cancer across the globe. The key factors driving growth of Immune Checkpoint Inhibitors market growth are attributed to increase in incidences of different forms of cancer, surge in awareness of checkpoint inhibitors for treatment of cancer, higher number of R&D studies, and surge in adoption of immune checkpoint inhibitor drugs. In addition, growth in geriatric population and technological advancements in screening & diagnosis of cancer further drives the market growth. However, high cost associated with immune checkpoint inhibitors is projected to impede the market growth.

The immune checkpoint inhibitors market is segmented on the basis of type, application, and region. On the basis of, the market is classified as CTLA-4 inhibitor, PD-1 inhibitor, PD-L1 inhibitor, and others. According application, it is categorized into lung cancer, bladder cancer, melanoma, Hodgkin lymphoma, and others. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Scope of The Report

What is the Impact of COVID-19 on Immune Checkpoint Inhibitors Market?

Coronavirus (COVID-19) was discovered in December 2019 in Hubei province of Wuhan city in China. The disease is caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is transmitted among humans. 

After its discovery in Wuhan, the disease rapidly spread to other parts of the globe. Moreover, this virus causes various symptoms in patients, which range from common symptoms to serious symptoms. For instance, common symptoms include fever, dry cough, and fatigue. However, serious symptoms include difficulty in breathing or shortness of breath, chest pain or pressure, and loss of speech or movement. Furthermore, the virus has high potential of lethality in geriatric population. On March 11, 2020, the World Health Organization made an assessment that COVID-19 can be characterized as pandemic. In addition, only a few vaccines that received emergency approvals for COVID-19 prevention. Thus, social distancing is observed as the most important measure to stop the spread of this disease. Furthermore, to maintain social distancing, various countries across the world have adopted nationwide lockdowns. 

Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/39336

The overall impact of COVID-19 remains negative on the immune checkpoint inhibitor market, owing to decline in number of cancer patients visits in hospitals and clinics for immune checkpoint inhibitor therapy (ICI) which lead to decline in the demand of Immune checkpoint inhibitors products. For instance, according to NCBI in 2020 around 50% of patient decrease is reported for cancer care in U.S. and overall cancer therapies are declined by 50% during COVID-19. Furthermore, WHO issued guidelines regarding the nonessential planned therapies such as for cancer and procedures based on the need of critical situations? The guidelines suggest to provide emergency services to patients who require urgent attention and postpone the therapies and surgery if not urgent, which lead to decline in the demand for immune check point products in the market. 

In addition, owing to the outbreak most of the markets are experiencing a decline especially immune checkpoint inhibitors market. For instance, according to AstraZeneca plc, Opidivo (immune checkpoint inhibitor) registered a 5.6% decline in 2020 due to decline in no of cancer patients visit in clinics and hospitals during COVID-19 which led to decline in the demand for immune check point products in the market.

By Type Segment Review

By type, the immune checkpoint inhibitors market is divided into CTLA-4 inhibitor, PD-1 inhibitor, PD-L1 inhibitor, and others. The PD-1 inhibitor segment was the major revenue contributor in 2020, and is anticipated to continue this trend during the forecast period, owing due to increase in adoption of PD-1 inhibitors such as pembrolizumab and nivolumab globally. On the other side, the demand for PD-L1 inhibitor is projected to exhibit the fastest immune checkpoint inhibitors market growth during the forecast period, owing to rise in use of durvalumab&avelumab and surge in R&D studies for PD-L1 inhibitors. 

By Application Segment Review

By application, the immune checkpoint inhibitors market is classified as lung cancer, bladder cancer, melanoma, Hodgkin lymphoma, and others. The lung cancer segment presently dominates the market, and is expected to remain dominant during the forecast period, due owing to increase in use of immune checkpoint inhibitors for the treatment of lung cancer and surge in prevalence of lung cancer globally. However, the bladder cancer segment is projected to show fastest growth during the forecast period, due owing to increase in incidences of bladder cancer.

By Region segment review

By region, the Immune checkpoint inhibitors market is analyzed across North America, Asia-Pacific, Europe, and LAMEA. North America dominated the market in 2020, accounting for the highest share, and is anticipated to maintain this trend throughout the forecast period. The research activities for immune checkpoints inhibitors are soaring in North America due to significant infrastructure for developmental research, availability of substantial research funds and growing government initiatives towards immune checkpoint inhibitors are anticipated to drive the market growth.

This report provides comprehensive competitive analysis and profiles of prominent market players such as Key players operating in the global immune checkpoint inhibitors market are, AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company (ARMO Biosciences.) GlaxoSmithKline Plc, F. Hoffmann-La Roche Ltd. (Genentech, Inc.,), Sanofi, Merck & Co., Inc., Merck KGaA (EMD Serono, Inc.), and BeiGene Ltd, Shanghai Jhunsi Biosciences Ltd. 

Key Benefits for Stakeholders

• This report provides a detailed quantitative analysis of the current Immune checkpoint inhibitors market trends and forecast estimations from 2020 to 2030, which assists to identify the prevailing market opportunities. 
• An in-depth market analysis includes analysis of various regions, which is anticipated to provide a detailed understanding of the current trends to enable stakeholders formulate region-specific plans.
• A comprehensive analysis of factors that drive and restrain the growth of the global is provided.
• The projections in this report are made by analyzing the current trends and future market potential from 2021 to 2030, in terms of value.
• An extensive analysis of various regions provides insights that are expected to allow companies to strategically plan their business moves.
• Key market players within the Immune checkpoint inhibitors market are profiled in this report and their strategies are analyzed thoroughly, which helps in understanding competitive outlook of the Immune checkpoint inhibitors market.

KEY PLAYERS

• • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company (ARMO Biosciences.)
  • GlaxoSmithKline PLC
  • F. Hoffmann-La Roche Ltd. (Genentech Inc.,)
  • Sanofi
  • Merck & Co., Inc.
  • Merck KGaA (EMD Serono Inc.)
  • BeiGene Ltd
  • Shanghai Jhunsi Biosciences Ltd.

Market Segments

• By Type
  • CTLA-4 Inhibitor
  • PD-1 Inhibitor
  • PD-L1 Inhibitor
• By Application
  • Lung Cancer
  • Bladder Cancer
  • Melanoma
  • Hodgkin lymphoma
  • Others
• By Region
  • North America
  • Europe
  • Asia-Pacific
  • LAMEA

Click Here to View Full Report Table of Contents

Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/39336

You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333